Sleep, hunger, weight, and the facts so far
Ipamorelin changed a hormone, but hasn't proved a benefit
Animal tests changed bone, hunger, fat, and a growth-linked blood protein called IGF-1. Patients didn't recover from bowel surgery any faster.
Ipamorelin changed animals, not health in people
Poor sleep or a sharp rise in hunger may catch your notice first. The word peptide means ipamorelin is a chain made from five protein parts.
The gland below your brain makes growth hormone. Ipamorelin prompted that gland without raising the stress hormone cortisol [1].
Animal tests found changes in hunger, body fat, and bone [4][7]. Rat bones grew while a growth-linked blood protein called IGF-1 stayed level [4].
The only patient trial watched the bowel start working after an operation. Ipamorelin did no better than a sugar pill in that test [3].
That trial can't promise better sleep, weight, or health for you. The effects page keeps personal reports apart from study results, so you can see which claims have human proof.
Ipamorelin prompts the gland that makes growth hormone
Amino acids are the parts your body uses to build protein. Five joined parts make ipamorelin, which is called a peptide.
Ghrelin, your hunger hormone, and ipamorelin affect the same part of the gland [1]. That action makes the growth gland send its hormone into your blood.
In 1998, researchers tested ipamorelin in cells, rats, and pigs. A small amount caused growth hormone to rise in pigs.
An older test drug, called GHRP-6 in study papers, was the comparison [1]. GHRP-6 took more to cause the same rise.
Ipamorelin also left cortisol and prolactin level. Those hormones help with stress and making breast milk, but this result doesn't prove better health.
Rats grew more bone, while mice gained fat
More bone may sound good, while more body fat may not. These animal results don't give one clear answer for your health.
Female rats received 18, 90, or 450 micrograms each day. Each amount was split into three daily shots for 15 days.
Daily bone growth rose from 42 micrometers to 44, 50, and 52 micrometers; a thousand of these tiny lengths fit inside one millimeter, so the changes were tiny [4]. Each increase was very small.
A growth-linked blood protein called IGF-1 stayed level during the rat test. The bones grew without a matching rise in the IGF-1 blood test.
Another study compared mice that made growth hormone with mice that couldn't. After two weeks, each group gained about 15% in body weight [7].
Both groups also added body fat, and a fat-linked hormone rose. Since both groups gained fat, growth hormone wasn't the only cause.
These findings came from animals, not people. The Ipamorelin research page walks through each test in order.
The human tests haven't shown better health
Human proof is much thinner than the animal work. The largest test followed 114 adults after bowel surgery.
Researchers called this a Phase 2 trial, meaning an early patient test. Each person got 0.03 milligrams per kilogram the person weighed.
The medicine entered a vein twice daily for seven days. Staff watched closely as the patients healed from bowel surgery.
Patients ate solid food after 25.3 hours on ipamorelin. The time was 32.6 hours with the placebo treatment.
That placebo looked like medicine but contained no drug. This gave the researchers a fair group for comparison.
The gap could have come from chance, so the trial missed its goal [3]. Almost everyone in both groups reported at least one side effect [3].
The sugar-pill group reported slightly more side effects. That makes it hard to blame those problems on ipamorelin alone.
Another test used 8 people at each amount. Their bodies removed about half the drug within 2 hours.
The largest rise in growth hormone came near 40 minutes [2]. Neither human test proves that ipamorelin will improve your health.
Ipamorelin has never been an approved medicine
Ipamorelin has never been approved as a medicine [3]. Novo Nordisk began testing it in the 1990s, but patient testing stopped early.
In 2024, the FDA reviewed ipamorelin acetate, a form made with a salt. Category 2 had let some pharmacies mix the drug while that review was under way.
FDA's page current as of April 22, 2026 lists ipamorelin acetate's nomination as withdrawn under 503A, which covers pharmacies making medicine for individual patients. Ipamorelin acetate stays in Category 2 under 503B for outsourcing facilities, with the safety concerns still on the page. The withdrawn request does not tell a pharmacy whether it may mix the drug. Removal did not mean the drug was safe; it ended that temporary pharmacy allowance.
The FDA review took place on October 29, 2024. Pharmacy access grew tighter, and sports groups ban ipamorelin as well.
The Ipamorelin effects page explains the main concerns. You can read them before making a choice.